Active Ingredient History
Vecuronium is a neuromuscular blocking agent. Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia. Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. Vecuronium is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Postoperative Complications (approved 1984)
Analgesics, Opioid (Phase 4)
Anesthesia (Phase 4)
Arthritis (Phase 4)
Arthropathy, Neurogenic (Phase 4)
Brain Injuries (Phase 4)
Cognition Disorders (Phase 4)
Coronary Disease (Phase 4)
Gallstones (Phase 4)
Laparoscopy (Phase 4)
Neuromuscular Blockade (Phase 4)
Osteoarthritis (Phase 4)
Postoperative Complications (Phase 4)
Rotator Cuff Injuries (Phase 4)
Vascular Diseases (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue